Also found in: Wikipedia.


an inhibitor of platelet aggregation used for prevention of thrombosis in patients with acute coronary syndrome or undergoing certain percutaneous coronary procedures; administered intravenously.



Pharmacologic class: Platelet aggregation inhibitor

Therapeutic class: Antiplatelet agent

Pregnancy risk category B


Decreases platelet aggregation by binding to platelet-receptor glycoprotein, preventing binding of fibrinogen to platelets, which causes thrombus formation


Injection: 10-ml vial (2 mg/ml), 100-ml vial (0.75 mg/ml)

Indications and dosages

Acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction)

Adults: 180 mcg/kg I.V. bolus over 1 to 2 minutes, followed by a continuous infusion of 2 mcg/kg/minute for up to 72 hours

Prevention of thrombosis related to percutaneous coronary intervention (PCI)

Adults: 180 mcg/kg I.V. bolus immediately before PCI, then a continuous infusion of 2 mcg/kg/minute, followed by a second 180-mcg/kg bolus 10 minutes after first bolus. Continue infusion until discharge or for up to 24 hours.

Dosage adjustment

• Renal impairment


• Hypersensitivity to drug or its components

• Severe hypertension

• Bleeding disorders or evidence of active abnormal bleeding within previous 30 days

• Renal dialysis

• Recent cerebrovascular accident

• Recent surgery

• Current or planned administration of another parenteral Gp IIb/IIIa inhibitor


Use cautiously in:

• renal insufficiency

• creatinine level below 2 mg/dl

• platelet count below 100,000/mm3

• elderly patients

• pregnant or breastfeeding patients

• children (safety and efficacy not established).


• Withdraw single bolus dose from 10-ml vial into syringe, and give by I.V. push over 1 to 2 minutes. Follow single I.V. bolus dose with continuous I.V. infusion given undiluted from 100-ml vial spiked with infusion set connected to infusion control device.

• Don't administer through same I.V. line as furosemide.

Adverse reactions

CNS: headache, dizziness, asthenia, syncope

CV: hypotension

GI: nausea, diarrhea, constipation

GU: hematuria

Hematologic: bleeding tendency, thrombocytopenia

Skin: flushing

Other: bleeding at femoral access site


Drug-drug. Clopidogrel, dipyridamole, nonsteroidal anti-inflammatory drugs, oral anticoagulants, thrombolytics, ticlopidine: increased risk of bleeding Other platelet aggregation inhibitors: serious bleeding

Drug-diagnostic tests. Platelets: decreased count

Drug-herbs. Most commonly used herbs: increased anticoagulant effect of eptifibatide

Patient monitoring

• Monitor vital signs and assess cardiovascular status, especially for syncope and hypotension.

• Monitor coagulation studies, CBC, and platelet count. Watch for signs and symptoms of abnormal bleeding or bruising and hematuria.

• Check carefully for bleeding at all sites of invasive procedures, particularly femoral access site.

Patient teaching

• Tell patient drug may cause serious adverse effects but can help prevent a heart attack. Reassure him that he'll be closely monitored during therapy.

Instruct patient to immediately report fainting or abnormal bruising or bleeding.

• Teach patient safety measures to avoid bruising or bleeding.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.


/ep·ti·fib·a·tide/ (ep″tĭ-fib´ah-tīd) an inhibitor of platelet aggregation used for the prevention of thrombosis in patients with acute coronary syndrome or undergoing certain percutaneous coronary procedures.


an antiplatelet agent.
indications It is used to treat acute coronary syndrome, including patients with percutaneous coronary intervention.
contraindications The following factors prohibit its use: known hypersensitivity to this drug, active internal bleeding, history of bleeding, stroke within 1 month, major surgery with severe trauma, severe hypotension, history of intracranial bleeding, intracranial neoplasm, arteriovenous malformation/aneurysm, aortic dissection, and dependence on renal dialysis.
adverse effects Life-threatening effects of this drug are stroke and bleeding. Hypotension is another serious adverse reaction.


Integrilin® Cardiology An antithrombotic GP IIb/IIIa receptor antagonist that blocks fibrinogen and von Willebrand factor from binding to the surface of activated platelets
References in periodicals archive ?
75gm, Benzathine Pencillin 6 Lac, Buscopan 1ml, Cerebrolysin Inj, Diltiazem 5mg/Ml, Eptifibatide 20mg/10ml,Fluconazole 25mg, Fosolin (FOSPHENYTOIN Sodium) D) Miscelleneous : 5 Mm Non Tooth Grasper With Handle, Adjustable Bed Side Table, Air Cushion Rings, Air Mattress, Antivirus Softwares Nod 32, Autoclave Tray, Barium Sulphate Solution, Bedside Locker, Biopsy Container 1000ml, Biopsy Container 2000ml, Botroclot Topical Solution, Cerelac Powder, Chromic Catgut Pre-Knotted Loop Ligature, Mis Contoured Rods (CURVED) All Sizes, Mis Rods Straight (ALL Sizes)
The Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early frontloaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome: study design and rationale.
Comparative antithrombotic effects of magnesium sulfate and the platelet glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide in a canine model of stent thrombosis.
Abciximab, eptifibatide and tirofiban are glycoprotein IIb/IIIa receptor antagonists.
5 x 24-mm drug-eluting stent was placed and she was given eptifibatide for 18 hours.
The patient was treated as an NSTEMI with heparin and eptifibatide infusion.
Ten patients (59%) received intravenous unfractionated heparin, with 2 patients (12%) receiving adjunctive eptifibatide, while the remaining 5 patients (29%) received bivalirudin (Figure 3).
Variability of platelet aggregate dispersal with glycoprotein llb-llla antagonists eptifibatide and abciximab.
The IR team attempted a clot retrieval and started eptifibatide (Integrillin) to minimize the damage.